P3-ULTRASIL 69 NEW

Glavne informacije

  • Zaščiteno ime:
  • P3-ULTRASIL 69 NEW (CLP)
  • Uporabi za:
  • ljudje
  • Vrsta medicine:
  • Medicinski pripomoček

Dokumentov

Lokalizacija

  • Na voljo v:
  • P3-ULTRASIL 69 NEW (CLP)
    Slovenija
  • Jezik:
  • slovenščina

Drugi podatki

Stanje

  • Source:
  • Ecolab
  • Številka dovoljenja:
  • 116116E
  • Zadnja posodobitev:
  • 12-03-2018

Glavnih Značilnosti Zdravila

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-ultrasil 69 NEW

116116E

1 / 13

ODDELEK 1: Identifikacija snovi/zmesi in družbe/podjetja

1.1 Identifikator izdelka

Ime proizvoda

P3-ultrasil 69 NEW

Koda proizvoda

116116E

Uporaba snovi/zmesi

Čistilo

Vrsta snovi

Zmes

Samo za poklicne uporabnike.

Podatki o redčenju izdelka

Podatkov o redčenju ni na voljo.

1.2 Pomembne identificirane uporabe snovi ali zmesi in odsvetovane uporabe

Identifikacija uporabe

Procesno čiščenje; Cleaning In place (CIP) postopek

Priporočene omejitve

uporabe

Samo za industrijsko in profesionalno uporabo.

1.3 Podrobnosti o dobavitelju varnostnega lista

Družba

Ecolab d.o.o.

Vajngerlova ulica 4

2000, Maribor Slovenija 02 429 3100 (Delavnik: 8:00 - 16:00)

narocila@ecolab.com

1.4 Telefonska številka za nujne primere

Telefonska številka za nujne

primere

+38682880010

+32-(0)3-575-5555 Transevropski

Telefonska številka Centra

za zastrupitve

Datum sestavitve/Revizije

21.09.2017

Verzija

ODDELEK 2: Ugotovitev nevarnosti

2.1 Razvrstitev snovi ali zmesi

Razvrstitev (UREDBA (ES) št. 1272/2008)

Jedkost za kožo, Kategorija 1.A

H314

Huda poškodba oči, Kategorija 1

H318

Razvrstitev temelji izključno na pH vrednosti proizvoda (skladno z veljavno evropsko zakonodajo).

2.2 Elementi etikete

Etiketiranje (UREDBA (ES) št. 1272/2008)

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-ultrasil 69 NEW

116116E

2 / 13

Piktogrami za nevarnost

Opozorilna beseda

Nevarno

Opozorila o nevarnosti

H314

Povzroča hude opekline kože in poškodbe oči.

Obvestila o nevarnosti

Preprečevanje:

P280

Nositi zaščitne rokavice/ zaščito za oči/ zaščito

za obraz.

Odziv:

P303 + P361 + P353

PRI STIKU S KOŽO (ali lasmi): Takoj sleči

vsa kontaminirana oblačila. Izprati kožo z

vodo/prho.

P305 + P351 + P338

PRI STIKU Z OČMI: previdno izpirajte z

vodo nekaj minut. Odstranite kontaktne leče,

če jih imate in če to lahko storite brez težav.

Nadaljujte z izpiranjem.

P310

Takoj pokličite CENTER ZA

ZASTRUPITVE/zdravnika.

Nevarne komponente, ki morajo biti naštete na nalepki/etiketi:

kalijev hidroksid

2.3 Druge nevarnosti

Nobena znana.

ODDELEK 3: Sestava/podatki o sestavinah

3.2 Zmesi

Nevarne sestavine

Kemijsko ime

Št. CAS

ES-št.

Št. REACH

RazvrstitevUREDBA (ES) št. 1272/2008

Koncentracija:

Kalijev karbonat

584-08-7

209-529-3

01-2119532646-36

Akutna strupenost Kategorija 4; H302

Draženje oči Kategorija 2; H319

Jedkost za kožo/draženje kože

Kategorija 2; H315

Specifična strupenost za ciljne organe

(STOT) - enkratna izpostavljenost

Kategorija 3; H335

>= 10 - < 20

kalijev hidroksid

1310-58-3

215-181-3

01-2119487136-33

Akutna strupenost Kategorija 4; H302

Jedkost za kožo Kategorija 1.A; H314

Jedko za kovine Kategorija 1; H290

>= 2.5 - < 5

Za celotno besedilo H-stavkov, omenjenih v tem Oddelku, glej Oddelek 16.

ODDELEK 4: Ukrepi za prvo pomoč

4.1 Opis ukrepov za prvo pomoč

Pri stiku z očmi

Takoj začeti izpirati z obilo vode, tudi pod vekami, najmanj 15

minut. Odstranite kontaktne leče, če jih imate in če to lahko storite

brez težav. Nadaljujte z izpiranjem. Takoj pokličite zdravnika.

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-ultrasil 69 NEW

116116E

3 / 13

Pri stiku s kožo

Takoj umivajte/izpirajte z obilo vode vsaj 15 minut. Po možnosti

uporabljati blago milo. Operite kontaminirana oblačila pred

ponovno uporabo. Pred uporabo temeljito očistiti obutev. Takoj

pokličite zdravnika.

Pri zaužitju

Izprati usta z vodo. NE izzivati bruhanja. Nikoli ne dajajte ničesar v

usta nezavestni osebi. Takoj pokličite zdravnika.

Pri vdihavanju

Premestiti na svež zrak. Simptomatsko zdravljenje. Če se pojavijo

simptomi, poiskati zdravniško pomoč.

4.2 Najpomembnejši simptomi in učinki, akutni in zapozneli

Glej Oddelek 11 za podrobnejše podatke o učinkih na zdravje in simptome.

4.3 Navedba kakršne koli takojšnje medicinske oskrbe in posebnega zdravljenja

Zdravljenje

Simptomatsko zdravljenje.

ODDELEK 5: Protipožarni ukrepi

5.1 Sredstva za gašenje

Ustrezna sredstva za

gašenje:

Uporabljajte gasilne ukrepe, ki so primerni lokalnim okoliščinam in

bližnjemu okolju.

Neustrezna sredstva za

gašenje

Nobena znana.

5.2 Posebne nevarnosti v zvezi s snovjo ali zmesjo

Specifične nevarnosti med

gašenjem

Ni vnetljivo ali gorljivo.

Nevarni proizvodi izgorevanja

Razkrojni produkti lahko vsebujejo naslednje snovi:

ogljikova oksida

Dušikovi oksidi (NOx)

Žveplovi oksidi

Fosforjevi oksidi

5.3 Nasvet za gasilce

Posebna zaščitna oprema za

gasilce

: Uporabljajte osebno varovalno opremo.

Dodatne informacije

: Ostanke po požaru in kontaminirano vodo za gašenje požara je

treba varno odstraniti v skladu z lokalnimi predpisi. Pri požaru

in/ali eksploziji ne vdihavajte dima.

ODDELEK 6: Ukrepi ob nenamernih izpustih

6.1 Osebni varnostni ukrepi, zaščitna oprema in postopki v sili

Nasvet za neizučeno osebje

Zagotovite zadostno prezračevanje. Preprečite ljudem dostop do

izpusta/razliva in v protivetrni smeri od izpusta/razliva. Izogibati se

vdihavanju, zaužitju ter stiku s kožo in očmi. Če so delavci

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-ultrasil 69 NEW

116116E

4 / 13

izpostavljeni koncentracijam nad dovoljenimi mejnimi vrednostmi,

morajo uporabljati ustrezno obrazno masko. Zagotovite, da

čiščenje izvaja samo usposobljeno osebje. Glej zaščitne ukrepe,

navedene v Oddelkih 7 in 8.

Nasvet za reševalce

Če so pri rokovanju z razlitjem zahtevana specialna oblačila,

upoštevati podatke o primernih in neprimernih materialih v

Oddelku 8.

6.2 Okoljevarstveni ukrepi

Okoljevarstveni ukrepi

Preprečiti, da pride v stik z zemljo, površinsko vodo ali podtalnico.

6.3 Metode in materiali za zadrževanje in čiščenje

Metode čiščenja

Zaustaviti puščanje, če je varno. Zajeziti in zadržati izlitje z

negorljivim absorpcijskim materialom (npr. peskom, zemljo,

diatomejsko zemljo, vermikulitom) in prenesti v vsebnik za

odstranjevanje skladno z lokalnimi/nacionalnimi predpisi (glej

Oddelek 13).Splakniti sledi z vodo. Pri večjih razlitjih zajeziti ali

drugače zadržati razlito snov in s tem zagotoviti, da ne doseže

vodotokov.

6.4 Sklicevanje na druge oddelke

Glej Oddelek 1 za podatke o kontaktu za nujne primere.

Glej Oddelek 8 za podatke o osebni zaščiti.

Glej Oddelek 13 za podatke o dodatni obdelavi odpadkov.

ODDELEK 7: Ravnanje in skladiščenje

7.1 Varnostni ukrepi za varno ravnanje

Navodilo za varno rokovanje

Ne zaužiti. Preprečiti stik z očmi, kožo ali oblačili. Ne vdihavati

prahu/dima/plina/meglice/hlapov/razpršila. Uporabljati samo ob

ustreznem prezračevanju. Po uporabi temeljito umiti roke.

Higienski ukrepi

Ravnajte v skladu z dobro proizvodno in varnostno prakso.

Odstranite in operite kontaminirana oblačila pred ponovno

uporabo. Po uporabi temeljito umiti obraz, roke in izpostavljeno

kožo. V primeru nevarnosti, kjer bi lahko prišlo do stika ali

brizganja, zagotoviti ustrezne prostore in pripomočke za hitro

polivanje ali izpiranje oči in telesa.

7.2 Pogoji za varno skladiščenje, vključno z nezdružljivostjo

Zahteve glede skladiščnih

prostorov in vsebnikov

Ne skladiščiti v bližini kislin. Hraniti zunaj dosega otrok. Hraniti v

tesno zaprti posodi. Hraniti v posodah z ustreznimi nalepkami.

Hraniti samo v originalni posodi. Odpraviti razlitje, da se prepreči

materialna škoda.

Temperatura pri skladiščenju

0 °C do 40 °C

Pakirni material

Primeren material: Polimeren material, vključno ekspandiran

polimeren material

Neprimeren material: Mehko jeklo, Aluminij

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-ultrasil 69 NEW

116116E

5 / 13

7.3 Posebne končne uporabe

Posebni način(-i) uporabe

Procesno čiščenje; Cleaning In place (CIP) postopek

ODDELEK 8: Nadzor izpostavljenosti/osebna zaščita

8.1 Parametri nadzora

Ne vsebuje snovi z mejnimi vrednostmi za poklicno izpostavljenost.

DNEL

kalijev hidroksid

Končna uporaba: Delavci

Načini izpostavljenosti: Vdihavanje

Vrednost: 1 mg/m3

Končna uporaba: Potrošniki

Načini izpostavljenosti: Vdihavanje

Vrednost: 1 mg/m3

8.2 Nadzor izpostavljenosti

Ustrezni inženirski mehanizmi

Tehnični ukrepi

Učinkovit izpušni prezračevalni sistem. Ohranjati vrednosti

koncentracij v zraku znotraj standardov za poklicno

izpostavljenost.

Individualni zaščitni ukrepi

Higienski ukrepi

Ravnajte v skladu z dobro proizvodno in varnostno prakso.

Odstranite in operite kontaminirana oblačila pred ponovno

uporabo. Po uporabi temeljito umiti obraz, roke in izpostavljeno

kožo. V primeru nevarnosti, kjer bi lahko prišlo do stika ali

brizganja, zagotoviti ustrezne prostore in pripomočke za hitro

polivanje ali izpiranje oči in telesa.

Zaščita za oči / obraz (EN

166)

Varovalna očala

Obrazni ščitnik

Zaščita rok (EN 374)

Priporočena preventivna zaščita kože

Rokavice

Nitrilni kavčuk

butilni kavčuk

Prebojni čas: 1 - 4 ure

Minimalna debelina rokavic iz butilne gume je 0.7mm, iz nitrilne

gume 0.4mm oz. enakovredno (upoštevati navodila

proizvajalca/distributerja rokavic).

Če se pojavijo kakršni koli znaki razkroja rokavic ali prodora

kemikalij skozi rokavice, je treba le-te odstraniti in jih zamenjati z

novimi.

Zaščita kože (EN 14605)

Osebna zaščitna oprema, vsebujoč: prilegajoče se zaščitne

rokavice, zaščitna očala in zaščitno obleko

Zaščita dihal (EN 143,

14387)

Ni potrebna, če se koncentracija nevarnih snovi v zraku ohrani

pod mejnimi vrednostmi, navedenimi v podatkih o mejnih

vrednostih izpostavitve. Uporabiti certificirano dihalno napravo,

skladno z zahtevami Direktiv 89/656/EGS in 89/686/EGS ali

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-ultrasil 69 NEW

116116E

6 / 13

enakovredno, kadar se tveganju za dihala ni mogoče izogniti s

tehničnimi varovalnimi sredstvi in ukrepi, metodami ali postopki

organizacije dela.

Nadzor izpostavljenosti okolja

Splošna navodila

: Razmislite o ukrepih glede zadrževanja okoli posod za

skladiščenje.

ODDELEK 9: Fizikalne in kemijske lastnosti

9.1 Podatki o osnovnih fizikalnih in kemijskih lastnostih

Videz

: tekočina

Barva

: rjava

Vonj

: lahen

12.5 - 13.5, 100 %

Plamenišče

Se ne upošteva.

Mejne vrednosti vonja

Ni primerno in/ali ni določeno za zmesi

Tališče/ledišče

Ni primerno in/ali ni določeno za zmesi

Začetno vrelišče in območje

vrelišča

Ni primerno in/ali ni določeno za zmesi

Hitrost izparevanja

Ni primerno in/ali ni določeno za zmesi

Vnetljivost (trdno, plinasto)

Ni primerno in/ali ni določeno za zmesi

Zgornja meja eksplozivnosti

Ni primerno in/ali ni določeno za zmesi

Spodnja meja eksplozivnosti

Ni primerno in/ali ni določeno za zmesi

Parni tlak

Ni primerno in/ali ni določeno za zmesi

Relativna gostota par/hlapov

Ni primerno in/ali ni določeno za zmesi

Relativna gostota

1.31 - 1.35

Topnost v vodi

topno

Topnost v drugih topilih

Ni primerno in/ali ni določeno za zmesi

Porazdelitveni koeficient: n-

oktanol/voda

Ni primerno in/ali ni določeno za zmesi

Temperatura samovžiga

Ni primerno in/ali ni določeno za zmesi

Toplotni razpad/razgradnja

Ni primerno in/ali ni določeno za zmesi

Viskoznost, kinematična

Ni primerno in/ali ni določeno za zmesi

Eksplozivne lastnosti

Ni primerno in/ali ni določeno za zmesi

Oksidativne lastnosti

Snov ali zmes ni razvrščena kot oksidativna.

9.2 Drugi podatki

Ni primerno in/ali ni določeno za zmesi

ODDELEK 10: Obstojnost in reaktivnost

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-ultrasil 69 NEW

116116E

7 / 13

10.1 Reaktivnost

Nevarne reakcije pri normalni uporabi niso znane.

10.2 Kemijska stabilnost

Stabilno pri normalnih pogojih.

10.3 Možnost poteka nevarnih reakcij

Nevarne reakcije pri normalni uporabi niso znane.

10.4 Pogoji, ki se jim je treba izogniti

Nobena znana.

10.5 Nezdružljivi materiali

Kisline

Kovine

Organski materiali

Mehko jeklo

Aluminij

10.6 Nevarni produkti razgradnje

Razkrojni produkti lahko vsebujejo naslednje snovi:

ogljikova oksida

Dušikovi oksidi (NOx)

Žveplovi oksidi

Fosforjevi oksidi

ODDELEK 11: Toksikološki podatki

11.1 Podatki o toksikoloških učinkih

Podatki o možnih načinih

izpostavljenosti

Vdihavanje, Stik z očmi, Stik s kožo

Proizvod

Akutna oralna strupenost

: Ocena akutne strupenosti : > 2,000 mg/kg

Akutna toksičnost pri

vdihavanju

: Za ta proizvod ni na voljo podatkov.

Akutna dermalna strupenost

: Za ta proizvod ni na voljo podatkov.

Jedkost za kožo/draženje

kože

: Za ta proizvod ni na voljo podatkov.

Resne okvare oči/draženje

: Za ta proizvod ni na voljo podatkov.

Preobčutljivost pri vdihavanju

in preobčutljivost kože

: Za ta proizvod ni na voljo podatkov.

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-ultrasil 69 NEW

116116E

8 / 13

Rakotvornost

: Za ta proizvod ni na voljo podatkov.

Učinki na razplojevanje

: Za ta proizvod ni na voljo podatkov.

Mutagenost za zarodne

celice

: Za ta proizvod ni na voljo podatkov.

Teratogenost

: Za ta proizvod ni na voljo podatkov.

STOT - enkratna

izpostavljenost

: Za ta proizvod ni na voljo podatkov.

STOT - ponavljajoča se

izpostavljenost

: Za ta proizvod ni na voljo podatkov.

Toksičnost pri vdihavanju

: Za ta proizvod ni na voljo podatkov.

Sestavine

Akutna oralna strupenost

: Kalijev karbonat

LD50 Podgana: 1,870 mg/kg

kalijev hidroksid

LD50 Podgana: 333 mg/kg

Sestavine

Akutna toksičnost pri

vdihavanju

: Kalijev karbonat

4 h LC50 Podgana: 5.26 mg/l

Sestavine

Akutna dermalna strupenost

: Kalijev karbonat

LD50 Kunec: 2,000 mg/kg

Možni učinki na zdravje

Oči

Povzroča hude poškodbe oči

Koža

Povzroča hude opekline kože.

Zaužitje

Povzroča opekline prebavnega trakta.

Vdihavanje

Lahko povzroči draženje nosu, grla in pljuč.

Kronična izpostavljenost

Pri normalni rabi ni znano ali pričakovano, da bi škodovalo

zdravju.

Izkušnje z izpostavljenostjo človeka

Stik z očmi

Rdečina, Bolečina, Razjede

Stik s kožo

Rdečina, Bolečina, Razjede

Zaužitje

Razjede, bolečina v trebuhu

Vdihavanje

Razdraženost dihal, Kašelj

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-ultrasil 69 NEW

116116E

9 / 13

ODDELEK 12: Ekološki podatki

12.1 Ekotoksičnost

Učinki na okolje

Ta proizvod nima znanih strupenih učinkov na okolje.

Proizvod

Strupenost za ribe

: Ni razpoložljivih podatkov

Strupenost za vodno bolho in

druge vodne vretenčarje.

: Ni razpoložljivih podatkov

Strupenost za alge

: Ni razpoložljivih podatkov

Sestavine

Strupenost za ribe

: Kalijev karbonat

96 h LC50 Ribe: 230 mg/l

12.2 Obstojnost in razgradljivost

Proizvod

Biorazgradljivost

: V proizvodu vsebovane površinsko aktivne snovi so

biorazgradljive v skladu z Uredbo o detergentih 648/2004/EC.

Sestavine

Biorazgradljivost

Kalijev karbonat

Rezultat: Se ne upošteva - anorgansko

kalijev hidroksid

Rezultat: Se ne upošteva - anorgansko

12.3 Zmožnost kopičenja v organizmih

Ni razpoložljivih podatkov

12.4 Mobilnost v tleh

Ni razpoložljivih podatkov

12.5 Rezultati ocene PBT in vPvB

Proizvod

Ocena

Snov/zmes ne vsebuje komponent, ki so obstojne,

bioakumulacijske in strupene (PBT) ali izredno obstojne in zelo

bioakumulacijske (vPvB) v koncentracijah 0,1% ali več.

12.6 Drugi škodljivi učinki

Ni razpoložljivih podatkov

ODDELEK 13: Odstranjevanje

Odložiti v skladu z evropskimi direktivami o odpadkih in nevarnih odpadkih.Odpadkom naj bi kode

pripisal uporabnik, prednostno po posvetu z organi, ki so pristojni za odstranjevanje odpadkov.

13.1 Metode ravnanja z odpadki

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-ultrasil 69 NEW

116116E

10 / 13

Proizvod

: Kjer je mogoče, ima recikliranje prednost pred odlaganjem ali

sežiganjem. Če recikliranje ni izvedljivo, odstraniti skladno z

lokalnimi predpisi. Odpad odlagajte v odobrenih objektih za

odlaganje odpada.

Kontaminirana

embalaža/pakiranje

: Odstranite kot nerabljen proizvod. Prazne posode je treba

dostaviti pooblaščeni osebi za ravnanje z odpadki na recikliranje

ali odlaganje. Prazni vsebniki niso za ponovno uporabo. Odstraniti

skladno z lokalnimi, državnimi in zveznimi predpisi.

Napotki za izbiro kode

odpadka

: Anorganski odpadki, ki vsebujejo nevarne snovi. Če se ta proizvod

uporablja v katerih koli nadaljnjih postopkih, mora končni

uporabnik opredeliti in določiti najprimernejšo kodo odpadka glede

na Evropski seznam odpadkov. Odgovornost povzročitelja

odpadkov je, da določi strupenost in fizikalne lastnosti nastalega

materiala ter določi ustrezne metode identifikacije in

odstranjevanje odpadkov, skladno z veljavnimi evropskimi (EU

Direktiva 2008/98/ES) in lokalnimi predpisi.

ODDELEK 14: Podatki o prevozu

Špediter/pošiljatelj/dobavitelj je odgovoren zagotoviti, da so embalaža, oznake in nalepke za

označevanje nevarnosti skladni z izbranim načinom prevoza.

Transport po kopnem (ADR/ADN/RID)

14.1 Številka ZN

1814

14.2 Uradno ime blaga ZN

RAZTOPINA KALIJEVEGA HIDROKSIDA

14.3 Razredi nevarnosti

prevoza

14.4 Embalažna skupina

14.5 Nevarnosti za okolje

14.6 Posebni previdnostni

ukrepi za uporabnika

Noben

Zračni transport (IATA)

14.1 Številka ZN

1814

14.2 Uradno ime blaga ZN

Potassium hydroxide solution

14.3 Razredi nevarnosti

prevoza

14.4 Embalažna skupina

14.5 Nevarnosti za okolje

14.6 Posebni previdnostni

ukrepi za uporabnika

None

Pomorski transport

(IMDG/IMO)

14.1 Številka ZN

1814

14.2 Uradno ime blaga ZN

POTASSIUM HYDROXIDE SOLUTION

14.3 Razredi nevarnosti

prevoza

14.4 Embalažna skupina

14.5 Nevarnosti za okolje

14.6 Posebni previdnostni

ukrepi za uporabnika

None

14.7 Prevoz v razsutem

stanju v skladu s Prilogo II k

Not applicable.

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-ultrasil 69 NEW

116116E

11 / 13

MARPOL 73/78 in Kodeksom

IBC

ODDELEK 15: Zakonsko predpisani podatki

15.1 Predpisi/zakonodaja o zdravju, varnosti in okolju, specifični za snov ali zmes

v skladu z Uredbo o

detergentih ES 648/2004

5 % ali več vendar manj kot 15 %: Fosfonati

Nacionalni predpis

Upoštevajte direktivo 94/33/ES o varstvo mladih ljudi pri delu.

Razred skladiščenja

Drugi predpisi

Zakon o kemikalijah

Pravilnik o tehničnih in organizacijskih ukrepih za skladiščenje

nevarnih kemikalij

Pravilnik o varovanju delavcev pred tveganji zaradi

izpostavljenosti kemičnim snovem pri delu (Uradni list RS, št.

100/01, 39/05, 53/07, 102/10, 43/11 -- ZVZD-1, 38/15)

Pravilnik o varovanju delavcev pred tveganji zaradi

izpostavljenosti rakotvornim ali mutagenim snovem

Pravilnik o osebni varovalni opremi, ki jo delavci uporabljajo pri

delu

Pravilnik o varovanju zdravja pri delu otrok, mladostnikov in

mladih oseb

Pravilnik o varovanju zdravja pri delu nosečih delavk, delavk, ki so

pred kratkim rodile ter doječih delavk

Zakon o varstvu okolja

Uredba o odpadkih

Uredba o ravnanju z embalažo in odpadno embalažo

Zakon o prevozu nevarnega blaga

15.2 Ocena kemijske varnosti

Izdelek vsebuje snovi, za katere se še vedno zahtevajo ocene kemijske varnosti.

ODDELEK 16: Drugi podatki

Način, na katerega je bila določena razvrstitev

UREDBA (ES) št. 1272/2008

Razvrstitev

Utemeljitev

Jedkost za kožo 1.A, H314

Na podlagi testnih podatkov.

Huda poškodba oči 1, H318

Na podlagi testnih podatkov.

Celotno besedilo H-stavkov

H290

Lahko je jedko za kovine.

H302

Zdravju škodljivo pri zaužitju.

H314

Povzroča hude opekline kože in poškodbe oči.

H315

Povzroča draženje kože

H319

Povzroča hudo draženje oči.

H335

Lahko povzroči draženje dihalnih poti.

Celotno besedilo drugih okrajšav

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-ultrasil 69 NEW

116116E

12 / 13

ADN - Evropski sporazum o mednarodnem prevozu nevarnih snovi po celinskih vodah; ADR -

Evropski sporazum o mednarodnem prevozu nevarnih snovi po cesti; AICS - Avstralski popis

kemičnih snovi; ASTM - Ameriško združenje za testiranje materialov; bw - Telesna teža; CLP -

Uredba o razvrščanju, označevanju in pakiranju; Uredba (ES) št. 1272/2008; CMR - Karcinogena,

mutagena strupena snov ali snov, strupena za razmnoževanje; DIN

- Standard nemškega

inštituta za standardizacijo; DSL - Seznam domačih snovi (Kanada); ECHA - Evropska agencija

za kemikalije; EC-Number - Evropska številka Skupnosti; ECx - Koncentracija, povezana z x%

odzivom; ELx - Stopnja obremenitve, povezana z x% odzivom; EmS - Načrt v sili; ENCS -

Obstoječe in nove kemične snovi (Japonska); ErCx - Koncentracija, povezana z x% odzivom

stopnje rasti; GHS - Globalno usklajeni sistem; GLP - Dobra laboratorijska praksa; IARC -

Mednarodna agencija za raziskave raka; IATA - Mednarodno združenje letalskih prevoznikov;

IBC - Mednarodni kodeks za gradnjo in opremo ladij, ki prevažajo nevarne kemikalije v razsutem

stanju; IC50 - Polovična največja inhibitorna koncentracija; ICAO - Mednarodna organizacija

civilnega letalstva; IECSC - Kitajski seznam obstoječih kemičnih snovi; IMDG - Mednarodni

kodeks za prevoz nevarnih snovi po morju; IMO - Mednarodna pomorska organizacija; ISHL -

Zakon

varnosti

zdravju

delu

(Japonska);

Mednarodna

organizacija

standardizacijo; KECI - Korejski seznam obstoječih kemikalij; LC50 - Smrtna koncentracija za

50% testirane populacije; LD50 - Smrtni odmerek za 50% testirane populacije (srednji smrtni

odmerek); MARPOL - Mednarodna konvencija o preprečevanju onesnaževanja morja z ladij;

n.o.s. - Nikjer drugje navedeno; NO(A)EC - Koncentracija brez opaznega (škodljivega) učinka;

NO(A)EL - Raven brez opaznega (škodljivega) učinka; NOELR - Stopnja obremenitve brez

opaznega učinka; NZIoC - Novozelandski popis kemikalij; OECD - Organizacija za gospodarsko

sodelovanje in razvoj; OPPTS - Urad za kemijsko varnost in preprečevanje onesnaževanja; PBT -

Snov, ki je obstojna, se kopiči v organizmih in je strupena; PICCS - Filipinski seznam kemikalij in

kemičnih snovi; (Q)SAR - (Kvantitativno) razmerje med strukturo in aktivnostjo; REACH - Uredba

(ES) št. 1907/2006 Evropskega parlamenta in Sveta o registriranju, vrednotenju, potrjevanju in

omejevanju kemikalij; RID - Pravilniki o mednarodnem železniškem prevozu nevarnega blaga;

SADT - Samopospešujoča temperatura razgradnje; SDS - Varnostni list; TCSI - Tajvanski popis

kemičnih snovi; TRGS - Tehnično pravilo za nevarne snovi; TSCA - Zakon o nadzoru strupenih

snovi (ZDA); UN - Združeni narodi; vPvB - Zelo obstojno in se zelo lahko kopiči v organizmih

Pripravil

Regulatory Affairs

Številke, navedene v varnostnem listu, so podane v obliki: 1,000,000=1 milijon in 1,000=1 tisoč.

0.1 = 1 desetina in 0.001 = 1 tisočina.

SPREMEMBE PODATKOV: Pomembne spremembe podatkov o predpisih in zdravju pri tej

popravljeni izdaji so nakazane s črto ob levem robu varnostnega lista.

Informacija v tem Varnostnem listu je pravilna po našem najboljšem znanju, informacijah in

prepričanju na dan njegove objave. Informacija je zasnovana samo kot napotilo za varno

rokovanje, uporabo, obdelavo/predelavo, shranjevanje/skladiščenje, transport, odstranjevanje in

izpust in ne sme biti interpretirana kot specifikacija jamstev in kakovosti. Informacija se nanaša

samo na označeni specifični material in morda ne bo veljavna za tak material, če bo uporabljen v

kombinaciji s kakšnim drugim materialom ali postopkom, razen če to ni posebej navedeno v

tekstu.

PRILOGA: SCENARIJI IZPOSTAVLJENOSTI

Snovi po DPD+:

:

Naslednje snovi so glavne sestavine, ki prispevajo k scenariju izpostavljenosti za zmesi, skladno z

metodologijo DPD+:

Pot

Snov

Št. CAS

Št. EINECS

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-ultrasil 69 NEW

116116E

13 / 13

Zaužitje

kalijev hidroksid

1310-58-3

215-181-3

Vdihavanje

kalijev hidroksid

1310-58-3

215-181-3

Kožno

kalijev hidroksid

1310-58-3

215-181-3

Oči

kalijev hidroksid

1310-58-3

215-181-3

vodno okolje

Ni snovi v sledeh

Fizikalne lastnosti snovi po DPD+:

Snov

Parni tlak

Topnost v vodi

Pow

Molska masa

kalijev hidroksid

1,120 g/l

56.11 g/mol

Za preračun, ali so vaši nadaljnji pogoji obratovanja in ukrepi za obvladovanje tveganja varni,

prosimo, izračunajte faktor tveganja na spodaj navedeni spletni strani:

www.ecetoc.org/tra

Kratek naslov scenarija

izpostavljenosti

Procesno čiščenje; Cleaning In place (CIP) postopek

Deskriptorji uporabe

Glavne skupine uporabnikov

Industrijske uporabe: uporabe snovi kot takih ali v pripravkih na

industrijskih lokacijah

Sektorji končne uporabe

SU3: Industrijske uporabe: uporabe snovi kot takih ali v pripravkih

na industrijskih lokacijah

Skupine postopkov

PROC1: Uporaba v zaprtih procesih, izpostavljenost ni verjetna

PROC8b: Prenos snovi ali pripravka (polnjenje/ praznjenje) iz/ v

posode/ velike vsebnike na namenskih napravah

Kategorije izdelka

PC35: Izdelki za pranje in čiščenje (vključno z izdelki na osnovi

topil)

Kategorije sproščanja v

okolje

ERC4: Industrijska uporaba procesnih pripomočkov, ki se vključijo

v izdelke, v procesih in izdelkih

21-11-2018

FDA approves new treatment for patients with acute myeloid leukemia

FDA approves new treatment for patients with acute myeloid leukemia

The FDA approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

FDA - U.S. Food and Drug Administration

21-11-2018

Implementation and verification of PBPK modelling codes of TCDD in rats and humans into Berkeley Madonna

Implementation and verification of PBPK modelling codes of TCDD in rats and humans into Berkeley Madonna

Published on: Tue, 20 Nov 2018 The goal of the current work was to implement and verify previously published rat and human PBPK modelling codes for TCDD into Berkeley Madonna. The US‐EPA has used these PBPK models in the reassessment of TCDD. A procurement contract has been set up to explore the possibilities to adequately run the models and reproduce previously published results. The implementation of the available codes in Berkeley Madonna was carried out at RIKILT‐WUR under the framework agreement wi...

Europe - EFSA - European Food Safety Authority Publications

20-11-2018

FDA approves first treatment specifically for patients with rare and life-threatening type of immune disease

FDA approves first treatment specifically for patients with rare and life-threatening type of immune disease

The FDA approved Gamifant (emapalumab-lzsg) for the treatment of pediatric (newborn and above) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. This FDA approval is the first for a drug specifically for HLH.

FDA - U.S. Food and Drug Administration

20-11-2018

Relevance of new scientific information (Santos‐Vigil et al., 2018*) in relation to the risk assessment of genetically modified crops with Cry1Ac

Relevance of new scientific information (Santos‐Vigil et al., 2018*) in relation to the risk assessment of genetically modified crops with Cry1Ac

Published on: Wed, 14 Nov 2018 Following a request from the European Commission, EFSA assessed the scientific publication by Santos‐Vigil et al. (2018). The outstanding question was whether or not the new scientific information contains elements that could lead the EFSA GMO Panel to reconsider the outcome of its previous risk assessments on genetically modified crops expressing Cry1Ac protein. Santos‐Vigil et al. (2018) investigated the allergenic potential and immunological effects of the Cry1Ac protei...

Europe - EFSA - European Food Safety Authority Publications

20-11-2018

Modification of the existing maximum residue levels for pyraclostrobin in soyabean

Modification of the existing maximum residue levels for pyraclostrobin in soyabean

Published on: Mon, 19 Nov 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant BASF SE submitted a request to the competent national authority in France to modify the existing maximum residue level (MRL) for the active substance pyraclostrobin in soyabean. The data submitted in support of the request were found to be sufficient to derive MRL proposals for soyabean. The applicant provided a new validated analytical method to control residues of pyraclostrobin on the commodity u...

Europe - EFSA - European Food Safety Authority Publications

20-11-2018

Modification of the existing maximum residue levels and setting of import tolerances for pyraclostrobin in various crops

Modification of the existing maximum residue levels and setting of import tolerances for pyraclostrobin in various crops

Published on: Mon, 19 Nov 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant BASF SE submitted two requests to the competent national authority in Germany. The first one, to modify the existing maximum residue levels (MRL) for the active substance pyraclostrobin in various crops and to set import tolerances for sugar canes and American persimmons; the second one to set import tolerances for pineapples and passion fruits/maracujas. The data submitted in support of the request...

Europe - EFSA - European Food Safety Authority Publications

19-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on a new qualified health claim for consuming oils with high levels of oleic acid to reduce coronary heart disease risk

Statement from FDA Commissioner Scott Gottlieb, M.D., on a new qualified health claim for consuming oils with high levels of oleic acid to reduce coronary heart disease risk

FDA issues a qualified health claim for oleic acid oils based on data showing it reduces cholesterols levels.

FDA - U.S. Food and Drug Administration

17-11-2018

Assessment of genetically modified soybean MON 89788 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐011)

Assessment of genetically modified soybean MON 89788 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐011)

Published on: Fri, 16 Nov 2018 Following the submission of application EFSA‐GMO‐RX‐011 under Regulation (EC) No 1829/2003 from Monsanto Europe, the Panel on Genetically Modified Organisms of the European Food Safety Authority (GMO Panel) was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application for the herbicide‐tolerant genetically modified soybean MON 89788, for food and feed uses, excluding cultivation within the European Union....

Europe - EFSA - European Food Safety Authority Publications

17-11-2018

Evaluation of confirmatory data following the Article 12 MRL review for picolinafen

Evaluation of confirmatory data following the Article 12 MRL review for picolinafen

Published on: Fri, 16 Nov 2018 The applicant BASF Agro B.V. submitted a request to the competent national authority in Germany to evaluate the confirmatory data that were identified for picolinafen in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, a new validated analytical method for enforcement of the residue in dry/high starch‐, high water content‐, high acid content‐ and high oil content commodities ...

Europe - EFSA - European Food Safety Authority Publications

16-11-2018

FDA approves new drug to treat travelers’ diarrhea

FDA approves new drug to treat travelers’ diarrhea

FDA approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers’ diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.

FDA - U.S. Food and Drug Administration

16-11-2018

Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDA’s efforts to hold industry accountable for fulfilling critical post-marketing studies of the benefits, safety of new drugs

Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDA’s efforts to hold industry accountable for fulfilling critical post-marketing studies of the benefits, safety of new drugs

The FDA is committed to making sure post-market studies are transparent to the public and that industry is fulfilling their PMRs and PMCs.

FDA - U.S. Food and Drug Administration

16-11-2018

Statement by FDA Commissioner Scott Gottlieb, M.D., on efforts to reduce animal testing through a study aimed at eliminating the use of dogs in certain trials

Statement by FDA Commissioner Scott Gottlieb, M.D., on efforts to reduce animal testing through a study aimed at eliminating the use of dogs in certain trials

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to reduce use of animals through a study aimed at eliminating the use of dogs in certain trials

FDA - U.S. Food and Drug Administration

16-11-2018

FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot

FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot

The FDA expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly.

FDA - U.S. Food and Drug Administration

16-11-2018

Setting of an import tolerance for pyraclostrobin in rice

Setting of an import tolerance for pyraclostrobin in rice

Published on: Thu, 15 Nov 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant BASF SE submitted a request to the competent national authority in Germany to set an import tolerance for the active substance pyraclostrobin in rice. The data submitted in support of the request were found to be sufficient to derive a maximum residue level (MRL) proposal for rice. Based on the risk assessment results, EFSA concluded that the short‐term intake of residues resulting from the use of p...

Europe - EFSA - European Food Safety Authority Publications

16-11-2018

Evaluation of confirmatory data following the Article 12 MRL review for pyraclostrobin

Evaluation of confirmatory data following the Article 12 MRL review for pyraclostrobin

Published on: Thu, 15 Nov 2018 The applicant BASF SE submitted a request to the competent national authority in Germany to evaluate the confirmatory data that were identified for pyraclostrobin in the framework of the MRL review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, residues trials supporting the existing use of pyraclostrobin on table grapes authorised in southern EU Member States and an analytical method for analysing residues of pyraclostrobin in ...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Results from 2018 National Youth Tobacco Survey show dramatic increase in e-cigarette use among youth over past year

Results from 2018 National Youth Tobacco Survey show dramatic increase in e-cigarette use among youth over past year

New findings from the National Youth Tobacco Survey show that more than 3.6 million middle and high school students were current (past 30 day) e-cigarette users in 2018.

FDA - U.S. Food and Drug Administration

15-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on proposed new steps to protect youth by preventing access to flavored tobacco products and banning menthol in cigarettes

Statement from FDA Commissioner Scott Gottlieb, M.D., on proposed new steps to protect youth by preventing access to flavored tobacco products and banning menthol in cigarettes

Statement from FDA Commissioner Scott Gottlieb, M.D., on proposed new steps to protect youth by preventing access to flavored tobacco products and banning menthol in cigarettes

FDA - U.S. Food and Drug Administration

15-11-2018

Assessment of genetically modified LLCotton25 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐010)

Assessment of genetically modified LLCotton25 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐010)

Published on: Wed, 14 Nov 2018 Following the submission of application EFSA‐GMO‐RX‐010 under Regulation (EC) No 1829/2003 from Bayer, the Panel on Genetically Modified Organisms of the European Food Safety Authority (GMO Panel) was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application for the herbicide‐tolerant genetically modified LLCotton25, for food and feed uses, import and processing, excluding cultivation within the EU. The d...

Europe - EFSA - European Food Safety Authority Publications

14-11-2018

Evaluation of confirmatory data following the Article 12 MRL review for cyazofamid

Evaluation of confirmatory data following the Article 12 MRL review for cyazofamid

Published on: Tue, 13 Nov 2018 The applicant ISK Biosciences Europe N.V. submitted a request to the competent national authority in France to evaluate the confirmatory data that were identified in the framework of the MRL review under Article 12 of Regulation (EC) No 396/2005 as not available. The data gap which was related to information on freezer storage conditions for the residue trials reported on potatoes, tomatoes and cucurbits with edible and inedible peel was considered satisfactorily addressed...

Europe - EFSA - European Food Safety Authority Publications

10-11-2018

Pest categorisation of Popillia japonica

Pest categorisation of Popillia japonica

Published on: Thu, 08 Nov 2018 00:00:00 +0100 The Panel on Plant Health performed a pest categorisation of Popillia japonica(Coleoptera: Scarabaeidae) for the EU. P. japonica is a distinguishable species listed in Annex IAII of Council Directive 2000/29/EC. It is native to Japan but established in the USA in the early 20th century. It spreads from New Jersey to most US states east of the Mississippi, some to the west and north into Canada. P. japonica feeds on over 700 plant species. Adults attack folia...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to strengthen and modernize agency’s oversight and reporting of inspections for sterile injectable drugs

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to strengthen and modernize agency’s oversight and reporting of inspections for sterile injectable drugs

FDA is taking steps to modernize the agency’s inspections program

FDA - U.S. Food and Drug Administration

8-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access program

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access program

The FDA is committed to the expanded access program which provides a pathway for patients to gain access to investigational drugs, biologics and medical devices for serious diseases and life-threatening conditions outside of clinical trials when no comparable or satisfactory approved alternative therapy options are available.

FDA - U.S. Food and Drug Administration

8-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research, on approval of OTC Primatene Mist to treat mild asthma

Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research, on approval of OTC Primatene Mist to treat mild asthma

FDA approves new version of OTC Primatene Mist inhaler to treat mild, intermittent asthma for people who have been diagnosed with asthma by their physician

FDA - U.S. Food and Drug Administration

7-11-2018

Sprout Creek Farm Recalls "Margie" Cheese Due to Listeria Monocytogenes

Sprout Creek Farm Recalls "Margie" Cheese Due to Listeria Monocytogenes

Sprout Creek Farm of Poughkeepsie, New York is recalling 132 wheels of "Margie" cheese, because it has the potential to be contaminated with Listeria monocytogenes. Listeria monocytogenes is an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems.

FDA - U.S. Food and Drug Administration

6-11-2018

Evaluation of confirmatory data following the Article 12 MRL review for kresoxim‐methyl

Evaluation of confirmatory data following the Article 12 MRL review for kresoxim‐methyl

Published on: Fri, 02 Nov 2018 00:00:00 +0100 The applicant BASF SE submitted a request to the competent national authority in Belgium to evaluate the confirmatory data that were identified for kresoxim‐methyl in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the confirmatory data requirement, a new study on the storage stability of kresoxim‐methyl residues in animal matrices was submitted. The data gap was considered ...

Europe - EFSA - European Food Safety Authority Publications

2-11-2018

FDA and DoD formalize collaboration to advance medical products in support of American military personnel

FDA and DoD formalize collaboration to advance medical products in support of American military personnel

FDA and DoD formalize collaboration to advance medical products in support of American military personnel. New Memorandum of Understanding aligns agency efforts to foster the development and use of safe and effective medical products for members of the U.S. military.

FDA - U.S. Food and Drug Administration

2-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s approval of Dsuvia and the FDA’s future consideration of new opioids

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s approval of Dsuvia and the FDA’s future consideration of new opioids

FDA announces approval of Dsuvia and new steps the agency may be taking to evaluate opioids.

FDA - U.S. Food and Drug Administration

2-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s continued efforts to address growing epidemic of youth e-cigarette use, including potential new therapies to support cessation

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s continued efforts to address growing epidemic of youth e-cigarette use, including potential new therapies to support cessation

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s continued efforts to address growing epidemic of youth e-cigarette use, including potential new therapies to support cessation

FDA - U.S. Food and Drug Administration

1-11-2018

Information required for dossiers to support demands for import of high risk plants, plant products and other objects as foreseen in Article 42 of Regulation (EU) 2016/2031

Information required for dossiers to support demands for import of high risk plants, plant products and other objects as foreseen in Article 42 of Regulation (EU) 2016/2031

Published on: Wed, 31 Oct 2018 00:00:00 +0100 Article 42 of the new Plant Health Law (Regulation (EU) 2016/2031 on protective measures against pests of plants), introduce a concept of “high risk plants, plant products and other objects” in relation to the presence of a pest risk of an unacceptable level for the Union territory, identified on the basis of a preliminary assessment to be followed by a risk assessment. Upon request of the European Commission (EC), the European Food Safety Authority (EFSA) d...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Updated review of the existing maximum residue levels for imazalil according to Article 12 of Regulation (EC) No 396/2005 following new toxicological information

Updated review of the existing maximum residue levels for imazalil according to Article 12 of Regulation (EC) No 396/2005 following new toxicological information

Published on: Tue, 30 Oct 2018 00:00:00 +0100 In compliance with Article 43 of Regulation (EC) No 396/2005, EFSA received a mandate from the European Commission to provide an update of the reasoned opinion on the review of existing maximum residue levels (MRLs) for imazalil published on 5 September 2017, taking into account the additional information provided on the toxicity of the metabolites R014821, FK‐772 and FK‐284. EFSA did not derive MRL proposals from the post‐harvest uses reported on citrus fru...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The product Bergazym® P100 contains a xylanase which is produced by a non‐genetically modified strain of Trichoderma reesei. The additive is available in a coated granular form and it is intended to be used as a zootechnical additive (functional group: digestibility enhancers) for chickens for fattening, and weaned piglets at the dose of 1,500 EPU/kg feed. The production strain and the additive were fully characterised in a previous assessment of the Panel o...

Europe - EFSA - European Food Safety Authority Publications

30-10-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., and Deputy Commissioner Anna Abram on the FDA’s new plan to advance plant, animal biotechnology innovation

Statement from FDA Commissioner Scott Gottlieb, M.D., and Deputy Commissioner Anna Abram on the FDA’s new plan to advance plant, animal biotechnology innovation

FDA announces new plan to advance the development of plant and animal biotechnology innovation

FDA - U.S. Food and Drug Administration

30-10-2018

Small increased risk of certain types of skin cancer associated with the use of hydrochlorothiazide

Small increased risk of certain types of skin cancer associated with the use of hydrochlorothiazide

There is a small increased risk of developing basal cell carcinoma and squamous cell carcinoma in long-term use of blood pressure medicine containing hydrochlorothiazide. This follows from a review of new studies and available data undertaken by the European Medicines Agency, EMA.

Danish Medicines Agency

30-10-2018

ANSES Newsletter in English - N°49 - October 2018

ANSES Newsletter in English - N°49 - October 2018

France - Agence Nationale du Médicament Vétérinaire

29-10-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA’s new consideration of labeling for sesame allergies

Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA’s new consideration of labeling for sesame allergies

Food allergies have touched the lives of most of us. Thousands of Americans experience life-threatening, food-related reactions each year, and an estimated 20 people die from them annually. In some cases, such reactions occur despite a careful reading of packaged food labels by conscientious consumers. To me, that’s unacceptable. The FDA is committed to advancing our efforts to help ensure that Americans have access to the information they need about common allergens in packaged foods.

FDA - U.S. Food and Drug Administration

26-10-2018

Multi-country outbreak of Listeria monocytogenes sequence type 8 infections linked to consumption of salmon products

Multi-country outbreak of Listeria monocytogenes sequence type 8 infections linked to consumption of salmon products

Published on: Thu, 25 Oct 2018 00:00:00 +0200 A multi-country outbreak of 12 listeriosis cases caused by Listeria monocytogenes sequence type (ST) 8 has been identified through whole genome sequencing (WGS) analysis in three EU/EEA countries: Denmark (6 cases), Germany (5) and France (1). Four of these cases have died due to or with the disease. It is likely that the extent of this outbreak has been underestimated since the outbreak was identified through sequencing and only a subset of the EU/EEA count...

Europe - EFSA - European Food Safety Authority Publications

25-10-2018

Nutrition Facts Label Reboot: A Tale of Two Labels

Nutrition Facts Label Reboot: A Tale of Two Labels

The Nutrition Facts Label (NFL) on packages consumers look at when they’re buying groceries or preparing a meal has undergone a makeover. The U.S. Food and Drug Administration (FDA) has changed it to reflect updated scientific findings and help consumers make better-informed choices about the foods their families eat. Until the deadlines, consumers may see two different versions on the products they buy: the original label they’ve been using, as well as the new label. The Consumer Update will emphasize...

FDA - U.S. Food and Drug Administration

25-10-2018

Safety of zinc chelate of methionine sulfate for the target species

Safety of zinc chelate of methionine sulfate for the target species

Published on: Wed, 24 Oct 2018 00:00:00 +0200 Zinc chelate of methionine sulfate is intended to be used as a nutritional additive (functional group: compounds of trace elements). The additive is zinc chelated with methionine in a molar ratio 1:1. It is intended to supply zinc as a nutritional additive to all animal species/categories. In 2017, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) adopted an opinion on the safety and efficacy of zinc chelate of methionine su...

Europe - EFSA - European Food Safety Authority Publications

24-10-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on how new regulatory authorities will assist the agency in more forcefully addressing opioid crisis; included as part of the newly enacted Substance Use-Disorder Prevention that Promotes Opioid Recove

Statement from FDA Commissioner Scott Gottlieb, M.D., on how new regulatory authorities will assist the agency in more forcefully addressing opioid crisis; included as part of the newly enacted Substance Use-Disorder Prevention that Promotes Opioid Recove

The SUPPORT Act grants FDA additional authorities to meaningfully advance efforts to combat the crisis of opioid addiction plaguing our nation.

FDA - U.S. Food and Drug Administration

24-10-2018

FDA approves new drug to treat influenza

FDA approves new drug to treat influenza

FDA approved Xofluza (baloxavir marboxil) to treat acute uncomplicated flu in patients 12 years old and older who have been symptomatic for less than 48 hours.

FDA - U.S. Food and Drug Administration

24-10-2018

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Published on: Tue, 23 Oct 2018 00:00:00 +0200 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of HOSTAZYM® X as a feed additive for sows in order to have benefit in piglets. The additive HOSTAZYM® X contains endo‐1,4‐beta‐xylanase and is available in liquid and solid formulations. This product is authorised as a feed additive for chickens for fattening, tu...

Europe - EFSA - European Food Safety Authority Publications

23-10-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to advance new ways to increase the availability of naloxone as one means for reducing opioid overdose deaths

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to advance new ways to increase the availability of naloxone as one means for reducing opioid overdose deaths

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to advance new ways to increase the availability of naloxone as one means for reducing opioid overdose deaths

FDA - U.S. Food and Drug Administration

23-10-2018

New Seasons Market Issues Allergy Alert on Undeclared Soy in Hot & Sour Broth

New Seasons Market Issues Allergy Alert on Undeclared Soy in Hot & Sour Broth

New Seasons Market is recalling 193 jars of New Seasons Market Hot & Sour Broth because it contains undeclared soy. People who have an allergy or severe sensitivity to soy run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

20-10-2018

Evaluation of confirmatory data following the Article 12 MRL review for dimethomorph

Evaluation of confirmatory data following the Article 12 MRL review for dimethomorph

Published on: Fri, 19 Oct 2018 00:00:00 +0200 The applicant BASF SE submitted a request to the competent national authority in Germany to evaluate the confirmatory data that were identified for dimethomorph in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. The submitted residue data on raspberries were satisfactorily addressing the data gaps on raspberries and blackberries. Considering the new information provided, it is appropri...

Europe - EFSA - European Food Safety Authority Publications

19-10-2018

Statement by FDA Commissioner Scott Gottlieb, M.D., on FDA’s new steps to help produce farmers, processors more effectively comply with food safety requirements

Statement by FDA Commissioner Scott Gottlieb, M.D., on FDA’s new steps to help produce farmers, processors more effectively comply with food safety requirements

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s new steps to help produce farmers, fresh-cut produce processors more effectively comply with food safety requirements

FDA - U.S. Food and Drug Administration

18-10-2018

Stewart’s Shops Issues Allergy Alert on Undeclared Milk in Cranberry Apple Refresher

Stewart’s Shops Issues Allergy Alert on Undeclared Milk in Cranberry Apple Refresher

Saratoga Springs, NY - Stewart’s Shops Corp. is recalling units of Stewart’s Shops brand Cranberry Apple Refresher 16 fluid oz. because the product may contain undeclared milk. People who have an allergy to milk run the risk of serious or life-threatening allergic reaction if they consume this product. Approximately 2,300 units of affected product were distributed in upstate New York and Southern Vermont.

FDA - U.S. Food and Drug Administration

18-10-2018

Scientific Opinion on Flavouring Group Evaluation 201 Revision 2 (FGE.201Rev2): 2‐alkylated, aliphatic, acyclic alpha,beta‐unsaturated aldehydes and precursors, with or without additional double‐bonds, from chemical subgroup 1.1.2 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 201 Revision 2 (FGE.201Rev2): 2‐alkylated, aliphatic, acyclic alpha,beta‐unsaturated aldehydes and precursors, with or without additional double‐bonds, from chemical subgroup 1.1.2 of FGE.19

Published on: Wed, 17 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to consider in this revision 2 of Flavouring Group Evaluation 201, the additional data on genotoxicity submitted by the Industry on two substances, 2‐methylpent‐2‐enal [FL‐no: 05.090] and 2 methylcrotonaldehyde [FL‐no: 05.095], from subgroup 1.1.2 of FGE.19. In FGE.201Rev1, the Panel concluded that further data were required in order to clarify the genotoxic poten...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

SLR Food Distribution Inc. Issues Alert on Undeclared Sulfites in Sugar Melon Candy

SLR Food Distribution Inc. Issues Alert on Undeclared Sulfites in Sugar Melon Candy

SLR Food Distribution Inc. of New Hyde Park, NY is recalling its 7.04oz package of SUGAR MELON CANDY / WAX GOURD because it contains undeclared sulfites. Consumers who have severe sensitivity to sulfites run the risk of serious or life-threatening allergic reactions if they consume this product.

FDA - U.S. Food and Drug Administration

17-10-2018

New Nan Fong Hong Trading Inc. Issues Allergy Alert on Undeclared Sulfites in Source Day Natural Treasures Dried Liquorice Slice

New Nan Fong Hong Trading Inc. Issues Allergy Alert on Undeclared Sulfites in Source Day Natural Treasures Dried Liquorice Slice

New Nan Fong Hong Trading Inc. is recalling its 16 oz (454g) packages of Source Day Natural Treasures Dried Liquorice Slice because they contain undeclared sulfites. Consumers who are allergic to sulfite allergens run the risk of serious or life-threatening allergic reactions if they consume this product.

FDA - U.S. Food and Drug Administration

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

16-10-2018

FDA and DHS increase coordination of responses to medical device cybersecurity threats under new partnership; a part of the two agencies’ broader effort to protect patient safety

FDA and DHS increase coordination of responses to medical device cybersecurity threats under new partnership; a part of the two agencies’ broader effort to protect patient safety

FDA and DHS announce partnership to address medical device cybersecurity threats

FDA - U.S. Food and Drug Administration

16-10-2018

Evaluation of confirmatory data following the Article 12 MRL review for teflubenzuron

Evaluation of confirmatory data following the Article 12 MRL review for teflubenzuron

Published on: Mon, 15 Oct 2018 00:00:00 +0200 The applicant BASF Agro BV submitted a request to the competent national authority in United Kingdom to evaluate the confirmatory data that were identified for teflubenzuron in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, a new metabolism study on leafy crops, a study investigating the nature of residues under standard hydrolytic conditions and a validated ...

Europe - EFSA - European Food Safety Authority Publications

15-10-2018

Statement by FDA Commissioner Scott Gottlieb, M.D., on FDA’s new steps to modernize drug development, improve efficiency and promote innovation of targeted therapies

Statement by FDA Commissioner Scott Gottlieb, M.D., on FDA’s new steps to modernize drug development, improve efficiency and promote innovation of targeted therapies

FDA issues two guidance documents to provide drug developers greater clarity and direction as they pursue the next generation of therapies and treatments for patients.

FDA - U.S. Food and Drug Administration

11-10-2018

FDA approves new DNA-based test to determine blood compatibility

FDA approves new DNA-based test to determine blood compatibility

FDA approves new DNA-based test to determine blood compatibility.Test is first of this type approved to report genotypes as final results

FDA - U.S. Food and Drug Administration

11-10-2018

Wild boar in focus: Review of existing models on spatial distribution and density of wild boar and proposal for next steps

Wild boar in focus: Review of existing models on spatial distribution and density of wild boar and proposal for next steps

Published on: Wed, 10 Oct 2018 00:00:00 +0200 This report provides a review of existing models for predicting the spatial distribution and abundance of wild boar at various scales (global, continental, national and regional) in order to inform the development of a new model to produce estimates of wild boar abundance at European level. The review identifies and discusses a range of models based on a wide variety of data types, corresponding to those targeted by the data collection model set by ENETwild,...

Europe - EFSA - European Food Safety Authority Publications

9-10-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines

FDA issued a new series of guidance documents that will advance the development of generic transdermal and topical delivery systems

FDA - U.S. Food and Drug Administration

5-10-2018

Consumer Alert: Sprout Creek Farm “Margie” Cheese Batch Recalled

Consumer Alert: Sprout Creek Farm “Margie” Cheese Batch Recalled

Today the New York State Department of Agriculture and Markets alerted consumers to a pasteurization problem with one of Sprout Creek Farm's pasteurized cow's milk cheeses, "Margie," made on 8/28/2018. Sprout Creek Farm is located in Poughkeepsie, NY. The reason for the recall is the air temperature at the start and end of the pasteurization process is required to be above 150deg F per the Grade "A" Pasteurized Milk Ordinance; the batch in question did not meet that standard. The recall pertains only to...

FDA - U.S. Food and Drug Administration

5-10-2018

FDA allows marketing of first self-fitting hearing aid controlled by the user

FDA allows marketing of first self-fitting hearing aid controlled by the user

FDA allows marketing of a new device, the Bose Hearing Aid, intended to amplify sounds for individuals 18 years or older with perceived mild to moderate hearing impairment (hearing loss). This is the first hearing aid authorized for marketing by the FDA that enables the user to fit, program and control the hearing aid on his or her own, without assistance from a health care provider.

FDA - U.S. Food and Drug Administration

20-11-2018

#FDA has set important new goal when it comes to device safety: ensuring that we’re consistently first in the world to identify and act upon device safety signals to protect patients.  https://go.usa.gov/xPAf7 pic.twitter.com/IATHeEUgHe

#FDA has set important new goal when it comes to device safety: ensuring that we’re consistently first in the world to identify and act upon device safety signals to protect patients. https://go.usa.gov/xPAf7 pic.twitter.com/IATHeEUgHe

#FDA has set important new goal when it comes to device safety: ensuring that we’re consistently first in the world to identify and act upon device safety signals to protect patients. https://go.usa.gov/xPAf7  pic.twitter.com/IATHeEUgHe

FDA - U.S. Food and Drug Administration

16-11-2018

Latuda (Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.p.A.)

Latuda (Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.p.A.)

Latuda (Active substance: lurasidone) - Centralised - Renewal - Commission Decision (2018)7674 of Fri, 16 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2713/R/20

Europe -DG Health and Food Safety

19-10-2018

New Safety Communication. @US_FDA   is sharing Updated Information To Reduce Potential Cardiac Surgery   Infection Risks Associated With the LivaNova 3T Heater-Cooler Systems. Read More:  https://go.usa.gov/xPnNW  #FDA #MedicalDevice

New Safety Communication. @US_FDA is sharing Updated Information To Reduce Potential Cardiac Surgery Infection Risks Associated With the LivaNova 3T Heater-Cooler Systems. Read More: https://go.usa.gov/xPnNW  #FDA #MedicalDevice

New Safety Communication. @US_FDA is sharing Updated Information To Reduce Potential Cardiac Surgery Infection Risks Associated With the LivaNova 3T Heater-Cooler Systems. Read More: https://go.usa.gov/xPnNW  #FDA #MedicalDevice

FDA - U.S. Food and Drug Administration

17-10-2018

#FDA issues new draft guidance now open for comment: Content of Premarket Submissions for Management of Cybersecurity in #MedicalDevices. Click to read:  https://go.usa.gov/xPRNF pic.twitter.com/1VPpgHdbic

#FDA issues new draft guidance now open for comment: Content of Premarket Submissions for Management of Cybersecurity in #MedicalDevices. Click to read: https://go.usa.gov/xPRNF pic.twitter.com/1VPpgHdbic

#FDA issues new draft guidance now open for comment: Content of Premarket Submissions for Management of Cybersecurity in #MedicalDevices. Click to read: https://go.usa.gov/xPRNF  pic.twitter.com/1VPpgHdbic

FDA - U.S. Food and Drug Administration

16-10-2018

#FDAapproves new drug for the treatment of breast cancer with certain gene mutations for adults:  https://go.usa.gov/xPNnH .pic.twitter.com/5mo0xuGCcK

#FDAapproves new drug for the treatment of breast cancer with certain gene mutations for adults: https://go.usa.gov/xPNnH .pic.twitter.com/5mo0xuGCcK

#FDAapproves new drug for the treatment of breast cancer with certain gene mutations for adults: https://go.usa.gov/xPNnH . pic.twitter.com/5mo0xuGCcK

FDA - U.S. Food and Drug Administration

5-10-2018

Devices flag! The FDA has allowed the marketing a new type of hearing aid, a self-fitted hearing aid controlled by the user. Interested reporters should check out our press release:  https://go.usa.gov/xPkuB 

Devices flag! The FDA has allowed the marketing a new type of hearing aid, a self-fitted hearing aid controlled by the user. Interested reporters should check out our press release: https://go.usa.gov/xPkuB 

Devices flag! The FDA has allowed the marketing a new type of hearing aid, a self-fitted hearing aid controlled by the user. Interested reporters should check out our press release: https://go.usa.gov/xPkuB 

FDA - U.S. Food and Drug Administration